Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Revive Meds vs Trimrose

Revive Meds
Graded #404

Higher grade

vs+1.5
Trimrose
Graded #440

Lower grade

The verdict

Revive Meds takes it — 56.9/100 to 55.4/100, but only just.

Revive Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Revive Meds (revive-meds.com, Revive Health Therapy) is a nationwide GLP-1 and longevity telehealth service that sells compounded semaglutide and dual-agonist tirzepatide, each combined with vitamin B12… Trimrose is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTrimrose +19
21
40
Dose & formulationEven
64
64
Clinical oversightRevive Meds +12
80
68
Labs & monitoringEven
52
52
FulfillmentRevive Meds +33
90
57
Contract termsTrimrose +2
53
55
Revive Meds · left barTrimrose · right bar

The numbers

MetricRevive MedsTrimrose
WeighScore56.9/10055.4/100
GradeCC
Scorecard rank#404#440
Semaglutide$369/mo (starting dose, compounded)Not disclosed
Tirzepatide$459/mo (starting dose, compounded)Not disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Revive Meds

Graded #404 · C

Strengths

  • Offers both compounded semaglutide and dual-agonist tirzepatide, each combined with vitamin B12 (cyanocobalamin) in a single injection
  • Pay-per-order model with no subscription, sign-up fees, or long-term commitment, and free shipping on every order
  • Names its six 503A compounding pharmacies and two prescribing physicians, which is unusually transparent on fulfillment
  • Available in all 50 states and HSA/FSA eligible through a Medical Necessity Letter
  • Prepaying 3 to 12 months cuts the effective cost to as low as $202/mo (semaglutide) or $300/mo (tirzepatide)

Where it loses points

  • Month-to-month pricing is steep: $369/mo semaglutide and $459/mo tirzepatide unless you prepay several months
  • No public price list; pricing appears only after you complete a full health intake and create an account
  • Not LegitScript-certified (no seal displayed on the site)
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
Trimrose

Graded #440 · C

Strengths

  • Free, no-cost, no-obligation online eligibility quiz before any commitment
  • Offers a choice of a weekly compounded GLP-1 injection or a daily oral option
  • Fully online — assessment, provider review, and home delivery with ongoing support

Where it loses points

  • Runs on the CareValidate white-label platform and isn't the medical provider itself — a support@carevalidate.com address is exposed on the site
  • Pricing isn't shown publicly; the cost and the specific compounded molecule appear only after you complete the eligibility quiz
  • The states served, pharmacy partner and any LegitScript/503A certification aren't disclosed on the public site
  • Markets 'up to 22.5% of body weight' — a trial figure for branded tirzepatide, not a guaranteed or compounded-specific outcome
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard